PDCD1 and cancer: Overall, our study population is an appropriate representative of real-world patients with cancer treated with a PD-1 or PD-L1 inhibitor [30,31,32,33], suggesting the validity of the data source to develop the prediction model of irHAEs associated with a PD-1 or PD-L1 inhibitor.